ArticleCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne2022
Nirmatrelvir-ritonavir for COVID-19.
Article in CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Real-world analysis of safety, tolerability, and adherence to nirmatrelvir-ritonavir (paxlovid) in primary care COVID-19 outpatients.Scientific reports · 2024Article
- Review
- Article
- Low-Data Drug Design with Few-Shot Generative Domain Adaptation.Bioengineering (Basel, Switzerland) · 2023Article
- The "outsized" role of the I-helix kink in human Cytochrome P450s.Clinical and translational medicine · 2023Article
- Advances and challenges in using nirmatrelvir and its derivatives against SARS-CoV-2 infection.Journal of pharmaceutical analysis · 2023Review
- COVID-19 and antiepileptic drugs: an approach to guide practices when nirmatrelvir/ritonavir is co-prescribed.European journal of clinical pharmacology · 2022Review
- Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal.Journal of biomedical science · 2022Review
- Renalism.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2022Article
- Benefits of nirmatrelvir-ritonavir remain unproven for some populations.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2022Article
- Drug Interactions With Nirmatrelvir-Ritonavir in Older Adults Using Multiple Medications.JAMA network open · 2022Article
- Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants.Signal transduction and targeted therapy · 2022Review
- Real-world effectiveness ofFrontiers in pharmacology · 2022Article
- Paxlovid: Mechanism of Action, Synthesis, andBioMed research international · 2022Review
Corrections and comments
- Commented on by
- Comment onRenalism.2022
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.